These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 10859160)
21. Pharmacokinetics of etidocaine in fetal and neonatal lambs and adult sheep. Pedersen H; Morishima HO; Finster M; Arthur GR; Covino BG Anesth Analg; 1982 Feb; 61(2):104-8. PubMed ID: 7198869 [TBL] [Abstract][Full Text] [Related]
22. Impaired biliary elimination of beta-glucuronidase-resistant "glucuronides" of valproic acid after intravenous administration in the rat. Evidence for oxidative metabolism of the resistant isomers. Dickinson RG; Kluck RM; Wood BT; Eadie MJ; Hooper WD Drug Metab Dispos; 1986; 14(2):255-62. PubMed ID: 2870903 [TBL] [Abstract][Full Text] [Related]
23. Placental transfer and renal elimination of cimetidine in maternal and fetal sheep. Mihaly GW; Jones DB; Morgan DJ; Ching MS; Webster LK; Smallwood RA; Hardy KJ J Pharmacol Exp Ther; 1983 Nov; 227(2):441-5. PubMed ID: 6631723 [TBL] [Abstract][Full Text] [Related]
24. Drug disposition and effects in the fetus. Rurak DW; Wright MR; Axelson JE J Dev Physiol; 1991 Jan; 15(1):33-44. PubMed ID: 1678754 [TBL] [Abstract][Full Text] [Related]
25. Trans-2-ene-valproic acid is less behaviorally teratogenic than an equivalent dose of valproic acid in rats. Fisher JE; Acuff-Smith KD; Schilling MA; Nau H; Vorhees CV Teratology; 1994 Jun; 49(6):479-86. PubMed ID: 7747269 [TBL] [Abstract][Full Text] [Related]
26. Urinary metabolites of valproic acid in epileptic patients. Katayama H; Watanabe M; Yoshitomi H; Yoshida H; Kimoto H; Kamiya A; Hayashi T; Akimura T Biol Pharm Bull; 1998 Mar; 21(3):304-7. PubMed ID: 9556166 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762 [TBL] [Abstract][Full Text] [Related]
28. Gas chromatography/negative ion chemical ionization mass spectrometry and liquid chromatography/electrospray ionization tandem mass spectrometry quantitative profiling of N-acetylcysteine conjugates of valproic acid in urine: application in drug metabolism studies in humans. Gopaul SV; Farrell K; Abbott FS J Mass Spectrom; 2000 Jun; 35(6):698-704. PubMed ID: 10862121 [TBL] [Abstract][Full Text] [Related]
29. Materno-fetal pharmacokinetics and fetal distribution of valproic acid in a pregnant rhesus monkey. Dickinson RG; Lawyer CH; Kaufman SN; Lynn RK; Gerber N; Novy MJ; Cook MJ Pediatr Pharmacol (New York); 1980; 1(1):71-83. PubMed ID: 6810290 [TBL] [Abstract][Full Text] [Related]
30. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Ornoy A Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988 [TBL] [Abstract][Full Text] [Related]
31. Characterization of thiol-conjugated metabolites of 2-propylpent-4-enoic acid (4-ene VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry. Tang W; Abbott FS J Mass Spectrom; 1996 Aug; 31(8):926-36. PubMed ID: 8799319 [TBL] [Abstract][Full Text] [Related]
32. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Hooper WD; Franklin ME; Glue P; Banfield CR; Radwanski E; McLaughlin DB; McIntyre ME; Dickinson RG; Eadie MJ Epilepsia; 1996 Jan; 37(1):91-7. PubMed ID: 8603632 [TBL] [Abstract][Full Text] [Related]
33. Anticonvulsant activity of metabolites of valproic acid. Löscher W Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):158-63. PubMed ID: 6784685 [TBL] [Abstract][Full Text] [Related]
34. The effect of aspirin on valproic acid metabolism. Abbott FS; Kassam J; Orr JM; Farrell K Clin Pharmacol Ther; 1986 Jul; 40(1):94-100. PubMed ID: 3087680 [TBL] [Abstract][Full Text] [Related]
35. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid. Lee MS; Lee YJ; Kim BJ; Shin KJ; Chung BC; Baek DJ; Jung BH Arch Pharm Res; 2009 Jul; 32(7):1029-35. PubMed ID: 19641884 [TBL] [Abstract][Full Text] [Related]
36. Concentration-dependent disposition of glucuronide metabolite of valproate. Yu HY; Shen YZ J Pharm Pharmacol; 2002 May; 54(5):633-9. PubMed ID: 12005358 [TBL] [Abstract][Full Text] [Related]
37. Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice. Löscher W; Nau H Arch Int Pharmacodyn Ther; 1982 May; 257(1):20-31. PubMed ID: 6810778 [TBL] [Abstract][Full Text] [Related]
38. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Hendrickx AG; Nau H; Binkerd P; Rowland JM; Rowland JR; Cukierski MJ; Cukierski MA Teratology; 1988 Oct; 38(4):329-45. PubMed ID: 3149039 [TBL] [Abstract][Full Text] [Related]
40. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites. Nau H; Helge H; Luck W J Pediatr; 1984 Apr; 104(4):627-34. PubMed ID: 6423793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]